Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of AMRX's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Jun 27, 2022
Questions asked 43 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 43 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 39 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2021

2022-06-27 to 2022-08-05 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2022-08-05
RevenueSegments
Note 26 - Segment Information, page F-66
SEC asked
Your disclosure on page F-12 indicates that you operate principally in the United States, India, and Ireland. Please revise future filings to disclose the amount of revenue and longlived assets that are attributed to the United States as well as any individual foreign country that is material. Refer to ASC 280-10-50-41.
AMRX answered
Over 99% of our consolidated net revenue for the years ended December 31, 2021 and 2020 was attributed to the United States. In response to the Staff’s comment, we expect to prospectively revise the segment disclosures in our 2022 Annual Report on Form 10-K as follows:

Net revenue from external customers is attributed to countries based on the location of the product shipment.
Rest of the answer

For the years ended December 31, 2022, 2021, and 2020, net revenue from external customers attributed to foreign countries was immaterial.

Should net revenue from external customers attributed to foreign countries become material in future years, we will update our disclosures.

Amneal

Pharmaceuticals, 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807

P.

908.947.3120 F. 908.947.3146 www.amneal.com

With respect to long-lived assets, we will prospectively revise the segment disclosures in our 2022 Annual Report on Form 10-K to separately present our long-lived assets in the United States, India and Ireland. The disclosure will be substantially in the form of the disclosure set forth below and will be updated, as appropriate, as of December 31, 2022.

Long-lived assets, which are comprised of property, plant and equipment, net and operating and financing lease right-of-use assets, are attributed based on physical location. Long-lived assets by country were as follows (in thousands):

December 31,

2021

2020

United States

$

388,818

416,637

India

189,885

121,046

Ireland

60,300

67,027

$ 639,003

$ 604,710

ASC

280-10-50-39 requires entity-wide segment disclosures of geographic revenue and long-lived assets in annual reporting periods only; accordingly, the foregoing changes will only be made to our Annual Reports on Form 10-K.

Read in the reply
In its next report

First report after the company's reply of Aug 4, 2022: 10-Q filed Aug 8, 2022 ↗, against the 10-Q filed May 6, 2022 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2022-08-05

Form S-4

2017-12-19 to 2018-02-06 · 42 questions · 4 letters from the SEC, 4 from the company
No closing letter
RevenueRisk factorsSegmentsDebtLiquidity and cashNon-GAAP measuresExecutive payIncome taxes
Questions and Answers about the Combination and the Special Meeting · Q: What Impax stockholder vote is required for the approval of each proposal , page 3
SEC asked (1)
Please disclose the percentage of outstanding shares entitled to vote held by directors, executive officers and their affiliates. See Item 3(h) of Form S-4. Summary Simplified Post-Combination Combined Company Structure Immediately Following Closing,
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 3 of Amendment No. 1.
Read in the reply
Questions and Answers about the Combination and the Special Meeting · Q: What Impax stockholder vote is required for the approval of each proposal , page 3
SEC asked (2)
With reference to page 71, please expand your disclosure to provide a brief description of how the PIPE Investment will affect the combined company structure, including how it will affect the distribution of voting rights and economic rights. Please also including a diagram either here or on page 71 that shows that PIPE investors will hold a combined 15% of New Amneal shares.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 12-13 of Amendment No. 1.
Read in the reply
Termination and Termination Fees, page 16
SEC asked (3)
Please revise your disclosure in this section to indicate that Impax will be required to pay a termination fee of $45 million if Impax terminates the BCA to enter into a Superior Proposal.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 18 of Amendment No. 1.
Read in the reply
Directors and Executive Officers of New Amneal After the Combination · Corporate Governance, page 19
SEC asked (4)
Please revise your disclosure in these sections, and elsewhere in your prospectus as appropriate, to reflect the fact that given the current projected ownership, TPG will be entitled to nominate one director to the board and the board may be expanded to accommodate such director.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 21 and 226 of Amendment No. 1.
Read in the reply
Risk Factors · General, page 25
SEC asked (5)
Please include a risk factor disclosing the exclusive forum provision in the New Amneal Charter.
AMRX answered
In response to the Staff’s request, the Company has added the requested risk factor on page 60 of Amendment No. 1.
Read in the reply
The Combined Company may not be able to generate sufficient..., page 54
SEC asked (6)
Please disclose your anticipated debt service obligation.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 57 of Amendment No. 1.
Read in the reply
The Combination · PIPE Investment, page 71
SEC asked (7)
We note your disclosure that following the Redemption, members of the Amneal Group will sell "Class A Common Stock and Class B-1 Common Stock" to the PIPE Investors. Please revise to clarify whether TPG will be the only PIPE Investor to receive Class B-1 Common Stock and the number of shares to be issued for each of Class A Common Stock and Class B-1 Common Stock.
Rest of the question

In addition, please disclose the anticipated effect of this sale on the proportion of the outstanding shares of Class A common stock held by former Impax stockholders.

AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 74-75 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (8)
We note your disclosure of the release of financial results showing a decrease in total revenues and higher net losses. Please explain the drivers for such fluctuations, why these results prompted the company to pursue other strategic alternatives, and why this ultimately led to pursuing the transaction with Amneal.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 77, 78 and 80 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (9)
We note references to Impax's prospects as a stand-alone company and other strategic alternatives and business development opportunities potentially available to Impax. Please disclose the alternatives considered and explain why the board chose not to pursue such alternatives.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 78-79 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (10)
Please disclose any relationships or agreements between Impax and Amneal, including between management, prior to April 25, 2017.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 77 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (11)
On page 73, you disclose that Mr. Bisaro expressed his preliminary view on April 29, 2017 that the equity split should be approximately 70% ownership of the Existing Amneal Members and approximately 30% ownership for Impax Stockholders. Please expand your disclosure to describe the considerations in proposing this equity split, including any valuation on which such proposal was based.
Rest of the question

Please provide similar disclosure for each counter offer in negotiating the equity split, including the final agreed-upon equity split. To the extent the board considered the trading price of Impax stock or whether Impax holders would receive a premium, please also disclose such considerations and how they impacted negotiations. In addition, please disclose the reasons for choosing to conduct an all-stock transaction.

AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 78, 79, 81 and 85 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (12)
We note your disclosure on page 74 that you met with representatives of Party B, Party C and Party D in June 2017 to have preliminary discussions with such parties. Please expand your disclosure to describe the type of company, the type of transaction discussed and the reason(s) why these transactions were not pursued. Please also disclose whether such contacts were solicited by Impax or were unsolicited.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 79 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (13)
Please disclose why the Board decided not to initiate an auction process as discussed at the meeting on September 11, 2017.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 81 of Amendment No. 1.
Read in the reply
Background of the Combination, page 72
SEC asked (14)
Please revise to disclose the negotiations surrounding the definition of an Intervening Event with respect to Impax's Fiduciary Outs. Please also disclose any material discussions by the Impax board in determining to forgo a Go-Shop period and agreeing to a $45 million termination fee in the event of a superior proposal.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 82, 83 and 84 of Amendment No. 1.
Read in the reply
Risks and Potential Negative Factors, page 83
SEC asked (15)
We note your disclosure that "no other potential counterparties have expressed an interest in any alternative transaction with Impax." This is inconsistent with your disclosure on page 74. Please explain.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 90 of Amendment No. 1 to clarify that no other potential counterparties have expressed an interest in any alternative transaction with Impax since September 21, 2017.
Read in the reply
Opinion of Impax's Financial Advisor, page 90
SEC asked (16)
Please explain why the four companies used in the Comparable Company Analysis for Impax were chosen over other similar companies that are also among the top generic U.S. pharmaceutical companies. Please provide similar disclosure for the analyses related to Amneal. Please also disclose the underlying data used to calculate the multiples for each company.
AMRX answered
In response to the Staff’s comment, additional disclosures have been included on pages 100 and 103 of Amendment No. 1.
Read in the reply
Opinion of Impax's Financial Advisor, page 90
SEC asked (17)
Please disclose the underlying data used to calculate the multiples in the Precedent Transactions Analysis, as well as the date, size and purchase price of each transaction. Please also clarify how the results of the precedent transaction analysis were used to determine that the merger consideration was fair.
Rest of the question

Please provide similar clarification with respect to the Equity Research Analysts' Price Targets, the Historical Trading Ranges and the Equity Research Analysts' Price Targets.

AMRX answered
In response to the Staff’s comment to disclose the underlying data used to calculate the multiples in the Precedent Transactions Analysis, as well as the date, size and purchase price of each transaction, additional disclosures have been included on page 101 of Amendment No. 1.

With respect to the Staff’s comment to clarify how the results of the precedent transaction analysis were used to determine that the merger consideration was fair, as disclosed on pages 106-107 of Amendment No.
Rest of the answer

1, in arriving at Morgan Stanley’s opinion, Morgan Stanley considered the results of all its analyses as a whole. Morgan Stanley notes that, because the transaction resulted in a change of control for Impax and not Amneal, Morgan Stanley did not conduct a precedent transaction analysis for Amneal and, as a result, there was no directly corresponding valuation methodology for Amneal to which the results of the

Impax precedent transaction analysis could be compared. Accordingly, in conducting its implied Impax value contribution analysis, Morgan Stanley did not utilize the Impax precedent transaction analysis. However, Morgan Stanley considered the results of the Impax precedent transaction analysis, including the range of implied equity values of Impax, as part of the mix of factors that it took into account in delivering its opinion.

With respect to the Equity Research Analysts’ Price Targets, the Historical Trading Ranges and the Equity Research Analysts’ Price

Targets clarification, as noted on pages 102-103 of Amendment No. 1, these calculations were presented for reference purposes only and were not relied upon for valuation purposes.

Read in the reply
Opinion of Impax's Financial Advisor, page 90
SEC asked (18)
We note your disclosure in the Discounted Cash Flow Analysis on page 98 that the implied equity value of Impax was $4 billion to $6.21 billion. Please clarify whether this is the implied equity value of Amneal. If not, please explain how you calculated this implied equity value for Impax.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 105 of Amendment No. 1.
Read in the reply
Opinion of Impax's Financial Advisor, page 90
SEC asked (19)
Please show the underlying calculations for each of the implied Impax value contribution ranges.
AMRX answered
In response to the Staff’s request, the Company has added additional disclosures on page 105 of Amendment No. 1.
Read in the reply
Certain Tax Consequences of the Combination, page 101
SEC asked (20)
Please remove the word "Certain" from the heading for this section. Please also revise to provide a firm opinion for each material tax consequence. To the extent that you use a short-form tax opinion, please revise to clearly state that the disclosure in this section is the opinion of counsel and to identify and articulate the opinions being rendered by counsel.
Rest of the question

Please also revise to remove the assumption that the merger and subsequent conversion will qualify as a reorganization within the meaning of Section 368(a) of the Code as this assumes the tax consequence at issue. Refer to Section III of Staff Legal Bulletin No. 19 for guidance.

AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages i, 8, 18 and 109 of Amendment No. 1 to remove the word “Certain” from the heading of the section. The Company has also revised the disclosure on page 110 of

Amendment No. 1 to remove the assumption that the merger and subsequent conversion will qualify as a as a reorganization within the meaning of Section 368(a) of the Code. Sullivan & Cromwell LLP, counsel to the Company, has provided a short-for tax opinion which has been filed as Exhibit 8.1 to Amendment No. 1. The disclosure in Amendment No.
Rest of the answer

1 and the tax opinion provided by Sullivan & Cromwell LLP have been revised to clearly state that the disclosure contained in this section of Amendment No. 1 is the opinion of counsel and to identify and articulate the opinions being rendered by counsel.

Read in the reply
Business · Amneal Business, page 111
SEC asked (21)
Your discussion here quantifies adjusted EDITDA; however, your presentation here lacks mention of the most comparable GAAP measure, which causes your presentation of non- GAAP measure here to be more prominent than the most directly comparable GAAP measure.
Rest of the question

Similarly, on page 114 under the heading "Recent Performance", you highlight that adjusted EBITDA for the year ended December 31, 2014 increased from adjusted EBITDA to the year ended December 31, 2016 without mention of the most comparable GAAP measure. See Question 102.10 of the updated Non-GAAP Compliance and Disclosure Interpretations issued on May 17, 2016, and revise your disclosures throughout the registration statement accordingly.

AMRX answered
In response to the Staff’s comment, the Company has revised the disclosures on pages 121, 124 and 128 of Amendment No. 1. In addition, the Company respectfully advises the Staff that it has reviewed all presentations of non-GAAP financial measures throughout the Registration Statement and made revisions to include the most directly comparable GAAP measure in Amendment No. 1.
Read in the reply
Recently Issued Accounting Pronouncements, page 152
SEC asked (22)
Please revise this section to address the recently issued accounting pronouncements from the registrant's perspective as a public business entity rather than Amneal's historical perspective as a nonpublic entity.
Rest of the question

Provide disclosure that clearly explains the differences between these perspectives as it applies to the dates the registrant going forward as a public business entity will be required to implement the respective guidance. Refer to Staff Accounting Bulletin 74. As part of your disclosure, clearly address the registrant's adoption of ASU 2014-09, including dates, methods, and expected impact of implementation.

AMRX answered
In response to the Staff’s comment, the Company has revised the disclosures in the Recently Issued Accounting Pronouncements section on pages 163-165 of Amendment No. 1. Specifically, the revised disclosure addresses the recently issued accounting pronouncements from New Amneal’s perspective as a public business entity.
Read in the reply
Comparison of Stockholders' Rights · Number of Directors, page 212
SEC asked (23)
Please revise your description of New Amneal Stockholder Rights to address TPG's eligibility to elect one director to the board. In addition, please disclose the "certain ownership criteria" that Amneal must meet in order to designate six nominees.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 225-226 of Amendment No. 1.
Read in the reply
Beneficial Ownership of Impax Common Shares, page 223
SEC asked (24)
Please revise the security ownership table to include (i) the number of common shares held by all directors and named executive officers of Impax as a group and (ii) an explanation of the amounts as to which each beneficial owner has sole voting power, shared voting power, sole investment power or shared investment power. See Item 403(b) and Instruction 2 to Item 403 of Regulation S-K.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 236-237 of Amendment No. 1.
Read in the reply
Directors and Executive Officers of New Amneal After the Combination, page 225
SEC asked (25)
Please provide the disclosure required by Item 402 of Regulation S-K for each person who will serve as an executive officer or director of the combined company. We note in particular that Mr. Chirag Patel and Mr. Chintu Patel will sever as directors. Refer to Item 18(a)(7) of Form S-4.
AMRX answered
The Company acknowledges the Staff’s comment and respectfully submits that the disclosure required by Item 402 of Regulation S-K is not required for Mr. Chirag Patel or Mr. Chintu Patel since Messrs. Patel and Patel are not expected to serve as executive officers of the combined company (rather they will only serve as non-employee directors) and they did not receive any compensation in respect of their service as non-employee directors of Amneal in 2017.
Rest of the answer

The disclosure required by Item 402 of Regulation S-K for persons currently serving for Impax who will continue to serve as executive officers or directors of the combined company is currently incorporated by reference to Impax’s Annual

Report on Form 10-K filed with the SEC on March 1, 2017 (which incorporates certain portions of the Schedule 14A proxy statement filed with the SEC on April 5, 2017), and the Company has provided additional disclosure for certain subsequent material executive compensation actions.

In response to the Staff’s request, the Company has revised the disclosure on page 207 of Amendment No. 1.

Read in the reply
Amneal Related Party Disclosures, page 229
SEC asked (26)
Please file the license and commercialization agreement with Adello Biologics, LLC and the License, Supply and Distribution Agreement with Gemni Laboratories, LLC dated April 13, 2016 as exhibits to the registration statement. In the alternative, please tell us why you are not required to file such agreements.
Rest of the question

Notes to Consolidated Financial Statements Annual Financial Statements of Amneal Pharmaceuticals LLC and Subsidiaries 2. Summary of Significant Accounting Policies, page FS-32

AMRX answered
The Company acknowledges the Staff’s request but respectfully advises the Staff that it believes neither such agreement is required to be filed as an exhibit to the Registration Statement. In particular, the Company believes it has disclosed all information required to be disclosed with respect to such agreements under Item 404 of Regulation S-K and that no other information related to such agreements or the related person in the context of each such agreement is material to the investment decision to be made by Impax stockholders in respect of the business combination
Rest of the answer

transaction.

The

Company also notes that it does not believe that either agreement is material to Amneal’s business (or, following the closing of the business combination, the Company’s business) and that it views each such agreement, which is focused on the licensing, development and commercialization of products, as being of the type that ordinarily accompanies the kind of business conducted by Amneal (and following the closing, the kind of business that will be conducted by the Company) in the generic pharmaceuticals industry. The Company notes that no current directors or officers of Amneal (or expected directors or officers of the Company) are party to either such agreement, the business of Amneal is not (and following the closing, the Company will not be) substantially dependent on either such agreement and that neither such agreement calls for the acquisition or sale of any material assets (including any property, plant or equipment) of Amneal or, following the closing, the Company.

Notes to Consolidated Financial Statements

Annual Financial Statements of Amneal Pharmaceuticals LLC and Subsidiaries

2. Summary of Significant Accounting Policies, page FS-32

Read in the reply
Amneal Related Party Disclosures, page 229
SEC asked (27)
Please tell us your consideration of providing the disclosures required under ASC 28010-50 related to segments. Specifically tell us why you do not provide the disclosures required by ASC 280-10-50-40 regarding revenues from external customers for each product and service or each group of similar product and service as well as the disclosures required byASC 280-10-50-41 regarding information about geographic areas.
Rest of the question

4. Trade Accounts Receivable, page FS-44

AMRX answered
The guidance in ASC 280, including the disclosure requirements in ASC

280-10-50, is applicable to public entities. A public entity is defined in ASC 280-10-20 as:

“A business entity or a not-for-profit entity that meets any of the following conditions:

a. It has issued debt or equity securities or is a conduit bond obligor for conduit debt securities that are traded in a public market (a domestic or foreign stock exchange or an over-the-counter market, including local or regional markets).

b.
Rest of the answer

It is required to file financial statements with the Securities and Exchange Commission (SEC).

c. It provides financial statements for the purpose of issuing any class of securities in a public market.”

The Company has concluded that Amneal did not meet the definition of a public entity, and therefore, the guidance in ASC 280 was not applicable.

4. Trade Accounts Receivable, page FS-44

Read in the reply
Amneal Related Party Disclosures, page 229
SEC asked (28)
You state in this footnote that you do not believe you are dependent upon any single customer. However, your risk factor on page 43 states that “the loss of any one or more of these or any other major customer or the substantial reduction in orders from any one or more of Amneal's major customers could have a material adverse effect upon Amneal's future operating results and financial condition.” Please revise your
Rest of the question

disclosure to address this inconsistency.

AMRX answered
In response to the Staff’s comment, the Company has revised the disclosures on pages 46 and FS-44 of Amendment No. 1.
Read in the reply
General
SEC asked (29)
Please provide us with copies of the materials that Morgan Stanley prepared and shared with the board of directors in connection with this transaction, including any board books, transcripts and summaries of oral presentations made to the board. We may have additional comments after we review those materials.
AMRX answered
The Company acknowledges the request for copies of materials, including board books, Morgan Stanley prepared and shared with the board of directions in connection with the transaction. The presentations are being provided to the Staff under separate cover by Morgan Stanley’s counsel on a confidential and supplemental basis pursuant to Rule

12b-4 under the Exchange Act of 1834, as amended, and Rule 418 under the Securities Act of 1933, as amended.
Rest of the answer

In accordance with such Rules, Morgan Stanley’s counsel has requested that such materials be returned promptly following completion of the Staff’s review thereof. Morgan Stanley’s counsel has also requested confidential treatment of such materials pursuant to the provisions of 17 C.F.R. § 200.83.

Read in the reply
General
SEC asked (30)
Please file as exhibits any employment agreements with persons who will serve as executive officers of the combined company.
AMRX answered
acknowledges the Staff’s comment and has filed Exhibits 10.5, 10.6 and 10.7 with Amendment No. 1 in response.
Read in the reply
General
SEC asked (31)
Please provide beneficial ownership disclosure of Amneal, as required by Item 18(a)(5)(ii) of Form S-4. See also Item 6(d) of Schedule 14A and Item 403 of Regulation S-K.
AMRX answered
The Company acknowledges the Staff’s comment, but respectfully notes that Amneal is neither the registrant nor the acquired company in the business combination transaction contemplated by the Registration Statement and is not soliciting proxies from Impax stockholders in connection with the transaction. For that reason, the Company respectfully advises the Staff that it does not believe a table of beneficial ownership disclosure under Item 18(a)(5)(ii) of Form S-4 is required to be included in the Registration Statement for Amneal.
Rest of the answer

However, to address the Staff’s comment, the Company has revised disclosure on page 73 of Amendment No. 1 to clarify that Amneal Holdings, LLC is currently the sole beneficial owner of all outstanding membership interests of Amneal and, immediately following the consummation of the

Combination and the PIPE Investment, will be the sole beneficial owner of all of the outstanding Amneal Common Units (other than Amneal Common Units held by Amneal Holdings, Inc.).

The Company also respectfully advises the Staff that the power to vote or make investment decisions with respect to the outstanding membership interests of Amneal held by Amneal Holdings, LLC resides solely with Amneal Holdings, LLC itself. Amneal Holdings, LLC is managed by a board of managers consisting of four individuals (which includes Chirag Patel and Chintu Patel) and which can only act by at least majority approval (and in most cases, unanimous approval). None of the members of the board of managers of Amneal Holdings, LLC may act alone to direct the voting or disposition of the membership interests or otherwise has voting or investment power over the outstanding membership interests of Amneal held by Amneal Holdings, LLC through their direct or indirect ownership interest in Amneal Holdings, LLC. As a result, no individual manager or member of Amneal

Holdings, LLC should be deemed a beneficial owner of any outstanding membership interests of Amneal.

* * *

Any questions or comments with respect to the Registration Statement may be communicated to the undersigned at (212) 558-4175 or by email ([email protected]). Please send copies of any correspondence relating to this filing to Catherine M. Clarkin by email and facsimile ((212) 291-9025) with the original by mail to Sullivan & Cromwell LLP, 125 Broad Street, New York, New York 10004.

Read in the reply
Structure of the Combination, page 11
SEC asked (1)
Please revise the organizational charts provided depicting the post-combination combined company structure immediately following closing and the post-PIPE investment combined company structure to identify New Amneal as the registrant. In addition, please revise your disclosure immediately above the organizational charts to clarify that Holdco and New Amneal are the same entity.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 11, 13, 73 and 75-76 of Amendment No. 2.
Read in the reply
The Combination · Background of the Combination, page 77
SEC asked (2)
We note your revisions in response to our prior comment 9 regarding the alternatives to the Potential Combination considered by the Impax board. Please expand your disclosure where appropriate to address why the board chose not to pursue such alternatives.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 79 and 80 of Amendment No. 2.
Read in the reply
The Combination · Background of the Combination, page 77
SEC asked (3)
We note your revisions to page 79 in response to our prior comment 12. Please further expand your disclosure to explain why you did not pursue further discussions with Party B and Party D.
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 79 and 80 of Amendment No. 2.
Read in the reply
Directors and Executive Officers of New Amneal After the Combination, page 238
SEC asked (4)
We note your response to our prior comment 25 that Mr. Chirag Patel and Mr. Chintu Patel are not expected to serve as executive officers of the combined company and that they did not receive any compensation in respect of their service as non-employee directors of Amneal in 2017 and reissue the comment.
Rest of the question

Item 18(a)(7) of Form S-4 requires disclosure for each person who will serve as a director or executive officer of the surviving company, and does not limit it to only persons who had the same role prior to the combination.

AMRX answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 238 and 241 of Amendment No. 2 to include disclosures required by Item 402 of Regulation S-K for Mr. Chirag Patel and

Mr. Chintu Patel, each of who will continue to serve as a director of the combined company.
Read in the reply
Where You Can Find More Information, page 257
SEC asked (5)
Please revise to incorporate by reference your Form 8-Ks filed on November 24, 2017, December 29, 2017 and January 9, 2018. See Item 11(a)(2) of Form S-4. Annual Financial Statements of Amneal Pharmaceuticals LLC and Subsidiaries 2. Summary of Significant Accounting Policies, page FS-32
AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 256 of Amendment No. 2.

Annual Financial Statements of Amneal Pharmaceuticals LLC and Subsidiaries

2. Summary of Significant Accounting Policies, page FS-32
Read in the reply
Where You Can Find More Information, page 257
SEC asked (6)
Your response to our prior comment 27 indicates that you concluded that Amneal Pharmaceuticals LLC did not meet the definition of a public entity in ASC 280-10-20. Please explain to us the basis for that conclusion. Include in your response your consideration as to whether condition c. is met that financial statements are provided for the purpose of issuing any class of securities in a public market. Exhibits
AMRX answered
The Company respectfully advises the Staff that it has considered condition c. of the definition of a public entity in ASC 280-10-20 and determined that Amneal Pharmaceuticals LLC (“Amneal”) did not meet the definition of a public entity in ASC 280-10-20. The Company concluded that Amneal was a non-reporting company being acquired in connection with the business combination transaction providing its financial statements under Item 17 of Form S-4.
Rest of the answer

Specifically, the Company considered the fact that the Registration Statement is being filed by the Company, a direct wholly owned subsidiary of Impax Laboratories, Inc.

(“Impax”), for the purpose of seeking Impax stockholder approval and issuing its shares to Impax stockholders in connection with a business combination transaction in which the Company is the legal acquirer and Amneal is one of the legal targets in connection with the transaction. While the transaction will be accounted for such that Amneal will be the accounting acquirer of Impax and its wholly owned subsidiary, we relied upon the guidance in FRM 2200.1 that “the determination of the target company should be based on the legal form of the transaction” and that “[t]he fact that the target company may be the acquiring company for accounting purposes does not change that analysis.” Accordingly, the Company believes that the historical financial statements for Amneal required to be included in the Registration Statement should be those of a company being acquired in connection with the business combination transaction, which are not required to include the disclosures in ASC 280-10-50 in its separate financial statements.

The Company also respectfully advises the staff that, following consummation of the transaction, the Company will meet the definition of a public entity in ASC 280-10-20 and will include the disclosures in ASC 280-10-50 in its financial statements for periodic reports as a reporting issuer following the transaction.

Read in the reply
Where You Can Find More Information, page 257
SEC asked (7)
We note your revisions in response to our prior comment 20 regarding removal of the word "Certain" from the heading of the section describing tax consequences of the combination. Please have counsel make a conforming change to its cross reference to this section in Exhibit 8.1.
AMRX answered
In response to the Staff’s request, the Company’s counsel has revised Exhibit 8.1 of Amendment No. 2.
Read in the reply
General
SEC asked (8)
We note your response that Amneal is not the "registrant" on Form S-4. However, we note that the intent of the Form S-4 is to disclose information relating to the operating entity so that investors will understand the nature of the businesses of the combined company.
Rest of the question

Accordingly, we note that throughout the Form S-4 you have provided disclosure for Amneal, such as in your business disclosure and financial statements, even though it is not the technical registrant. Please similarly provide the disclosure required by Item 18(a)(5)(ii) of Form S-4 for Amneal, including beneficial ownership for Amneal Holdings, LLC, who serves as parent to Amneal.

AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 238 of Amendment No. 2.

* *

*

Any questions or comments with respect to Amendment No. 2 may be communicated to the undersigned at (212) 558-4175 or by email ([email protected]). Please send copies of any correspondence relating to this filing to Catherine M. Clarkin by email and facsimile ((212) 291-9025) with the original by mail to Sullivan & Cromwell LLP, 125 Broad Street, New York, New York 10004.
Read in the reply
The Combination · Structure of the Combination, page 73
SEC asked
We note your disclosure on page 75 that following the Closing and the PIPE Investment, it is expected that Existing Amneal Members will hold "approximately 60% of the voting power and no economic interest of the outstanding New Amneal Shares (assuming the conversion of all Amneal Common Units into shares of Class A Common Stock)." However, the percentages of voting power and economic interest provided do not appear
Rest of the question

to account for the conversion of all Amneal Common Units into shares of Class A Common Stock. Please revise your disclosure here and elsewhere as appropriate to provide the impact to the voting power and economic interest of Former Impax Stockholders, PIPE Investors and Existing Amneal Members of the conversion of all Amneal Common Units into shares of Class A Common Stock.

AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on pages 13 and 76 of Amendment No. 3.

* * *

Any questions or comments with respect to Amendment No. 3 may be communicated to the undersigned at (212) 558-4175 or by email ([email protected]). Please send copies of any correspondence relating to this filing to Catherine M. Clarkin by email and facsimile ((212) 291-9025) with the original by mail to Sullivan & Cromwell LLP, 125 Broad Street, New York, New York 10004.
Read in the reply
Questions and Answers about the Combination and the Special Meeting · What are the material U.S. federal income tax consequences..., page 8
SEC asked (1)
Please remove your assumption that the merger and conversion will qualify as a reorganization under Section 368(a) of the U.S. Internal Revenue Code. Please revise your disclosure to reflect that counsel has provided a firm opinion on this issue and clearly state that the disclosure in the tax consequences section is the opinion of counsel. Please also remove the disclaimer that the material U.S.
Rest of the question

federal income tax consequences is intended to provide only a general discussion as investors are entitled to rely on the opinion. For guidance, refer to Sections III.C.3 and III.D.1 of Staff Legal Bulletin No. 19 (Oct. 14, 2011).

AMRX answered
In response to the Staff’s request, the Company has revised the disclosure on page 8 of Amendment No. 4.
Read in the reply
Directors and Executive Officers of New Amneal After the Combination · Executive Officers of New Amneal, page 245
SEC asked (2)
Please file your employment agreement with Andrew Boyer as an exhibit to the registration statement. Refer to Item 601(b)(10)(iii)(A) of Regulation S-K.
AMRX answered
In response to the Staff’s comment, the Company has filed Mr. Boyer’s employment agreement as Exhibit 10.8 to Amendment No. 4.

* *

*

Any questions or comments with respect to Amendment No. 4 may be communicated to the undersigned at (212) 558-4175 or by email ([email protected]). Please send copies of any correspondence relating to this filing to Catherine M. Clarkin by email and facsimile ((212) 291-9025) with the original by mail to Sullivan & Cromwell LLP, 125 Broad Street, New York, New York 10004.
Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 12 letters filed since 2017-12-19. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.